Kennedy Capital Management, Inc. Janux Therapeutics, Inc. Transaction History
Kennedy Capital Management, Inc.
- $4.23 Billion
- Q4 2024
A detailed history of Kennedy Capital Management, Inc. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 12,713 shares of JANX stock, worth $386,856. This represents 0.02% of its overall portfolio holdings.
Number of Shares
12,713
Previous 11,785
7.87%
Holding current value
$386,856
Previous $535,000
27.1%
% of portfolio
0.02%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
229Shares Held
55.2MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$315 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$108 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$107 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$93.2 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$71.3 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.27B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...